Expression of splice variants of CD44 in thyroid neoplasms derived from follicular cells

Pathology International

Volumn 48, Issue 3, 1998, Pages 184-190

  Gu, Jing ^a   Daa, Tsutomu ^a   Kashima, Kenji ^a   Yokoyama, Shigeo ^a   Nakayama, Iwao ^a   Noguchi, Shiro ^b  

^a OITA UNIVERSITY   (Japan)

^b Noguchi Thyroid Clin/Hosp Found   (Japan)

Author keywords

Base sequencing; CD44 splice variants; Immunohistochemistry; RT PCR; Thyroid neoplasm

Indexed keywords

HERMES ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR BIOPSY;

EID: 0031948876     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03891.x     Document Type: Article

References (23)

1. Edelman GM. Cell adhesion and the molecular processes of morphogenesis. Annu. Rev. Biochem. 1985; 54: 135-169.
2. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv. Immunol. 1993; 54: 271-335.
3. Jalkanen S, Reichert RA, Gallatin WM, Bargatze RF, Weissman IL, Butcher EC. Homing receptors and the control of lymphocyte migration. Immunol. Rev. 1986; 91: 39-60.
4. Jalkanen S, Bargatze RF, de los Toyos J, Butcher EC. Lymphocyte recognition of high endothelium: Antibodies to distinct epitopes of an 85-90 kDa glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol. 1987; 105: 983-990.
5. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313.
6. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl Acad. Sci. USA 1992; 89: 12 160-12 164.
7. Brooks L, Niedobitek G, Agathanggelou A, Farrell PJ. The expression of variant CD44 in nasopharyngeal carcinoma is unrelated to expression of LMP-1. Am. J. Pathol. 1995; 146; 1102-1112.
8. Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
9. Rudy W, Hofmann M, Schwartz-Albiez R et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Res. 1993; 53: 1262-1268.
10. Seiter S, Arch R, Reber S et al. Prevention of tumor metastasis formation by anti-variant CD44. J. Exp. Med. 1993; 177: 443-455.
11. Wielenga VJ, Heider KH, Offerhaus GJ et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993; 53: 4754-756.
12. Kainz C, Kohlberger P, Sliutz G et al. Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol. Oncol. 1995; 57: 383-387.
13. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615-619.
14. Li H, Hamou MF, de Tribolet N et al. Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res. 1993; 53: 5345-5349.
15. Figge J, del Rosario AD, Gerasimov G et al. Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma. Exp. Mol. Pathol. 1994; 61: 203-211.
16. Ermak G, Gerasimov G, Troshina K et al. Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and non-neoplastic lesions of the human thyroid. Cancer Res. 1995; 55: 4594-4598.
17. Ermak G, Jennings T, Robinson L, Ross JS, Figge J. Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma. Cancer Res. 1996; 56: 1037-1042.
18. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumors. In: World Health Organization International Histological Classification of Tumors. Springer-Verlag, Berlin, 1988; 3-11.
19. Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor: Comparison of all 10 variable exons between mouse, human, and rat. J. Biol. Chem. 1993; 268: 12235-12238.
20. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992; 340: 1053-1058.
21. Arch R, Wirth K, Hofmann M et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992; 257: 682-685.
22. Woodman AC, Sugiyama M, Yoshida K et al. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am. J. Pathol. 1996; 149: 1519-1530.
23. Tanabe KK, Saya H. The CD44 adhesion molecule and metastasis. Crit. Rev. Oncog. 1994; 5: 201-212.